Research map: Lunsotogene Parvec: First Approval

Back to the article

Papers in this map

  1. Auditory neuropathy — neural and synaptic mechanisms · Tobias Moser · 2016 · 366 citations · Cited by this paper
  2. Sibeprenlimab: First Approval · 2026 · Related
  3. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model · Omar Akil · 2019 · 307 citations · Cited by this paper
  4. The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · 2026 · Related
  5. A dual‐AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock‐out mice · Hanan Al‐Moyed · 2018 · 231 citations · Cited by this paper
  6. Ecnoglutide: First Approvals · 2026 · Related
  7. DB-OTO Gene Therapy for Inherited Deafness · Vassili Valayannopoulos · 2025 · 70 citations · Cited by this paper
  8. Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · 2026 · Related
  9. The natural history, clinical outcomes, and genotype–phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review · Charles L. Ford · 2023 · 42 citations · Cited by this paper
  10. Etripamil: First Approval · 2026 · Related
  11. OTOF-related gene therapy: a new way but a long road ahead · Jieyu Qi · 2025 · 30 citations · Cited by this paper
  12. Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · 2026 · Related
  13. Functional, sustained recovery of hearing in Otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy · Yoojin Chung · 2025 · 17 citations · Cited by this paper
  14. Emerging Cardiorenal Protective Therapies in Lupus Nephritis · 2026 · Related
  15. Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · 2026 · Related
  16. Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here · 2026 · Related

Source: OpenAlex (CC0)